6 studies were found.

1.		No longer recruiting	Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin Conditions: squamous cell carcinoma of unknown primary; newly diagnosed carcinoma of unknown primary; undifferentiated carcinoma of unknown primary; ...
2.		No longer recruiting	Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Conditions: stage IIIA non-small cell lung cancer; stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer
3.		Recruiting	Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin Conditions: stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
4.		No longer recruiting	Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer
5.		No longer recruiting	Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Conditions: stage IIIA non-small cell lung cancer; stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer
6.		No longer recruiting	Temozolomide in Treating Women With Advanced Breast Cancer Conditions: stage IIIB breast cancer; stage IIIA breast cancer; stage IV breast cancer; recurrent breast cancer